Cannabis and Hemp Industry Investment News
Medlab continues the offshore expansion of its nutraceuticals business with a UK partner following its US initiative announced in October. Medlab is d...
Over 100 Australian doctors and 200 patients have been enrolled in the observational study. Patients participating in the study have reported a reduct...
Study timelines are progressing as planned and at this point the trial should complete ahead of expectations. The company is seeking to expand commerc...
The company has two key divisions, pharmaceutical and nutraceutical. Medlab’s nutraceutical divisions allow for revenue generation, brand and company ...
First revenues from the commercial agreements are expected in early 2020. The US dietary supplements market was valued at US$124.8 billion in 2018 wit...
The company’s first NanoCBD sale offers validation of the product and differentiated delivery technology and points to the global prospects for Medlab...
The clinical study was a blinded, randomised trial showing plasma concentrations were achieved quickly with a product half-life of about four hours. M...
What are you searching for? viewMedlab Clinical Ltd Both companies are now working on both the definitive agreement and product market launch. The dea...
Medlab is a medical research company with a track record of bringing its nutraceutical and cannabis products to market. Medlab shares are trading up 1...
Medlab expects to roll this trial out to 2,000 patients across Australia, making it one of the most significant cannabis trials to date. NanaBis could...
The agreement is with a major international Thai pharmaceutical company. This follows a similar deal with Canada’s fourth largest generic pharmaceutic...
() chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist...
Medlab has two cannabis-based medicines, NanaBis™ and NanaBidial™. NanaBis™ is currently in clinical trial at Royal North Shore Hospital () has entere...
The company is pleased with data it has collected to date for NanaBis. Medlab also sees a regulatory pathway for NanaBis to become an approved drug ’s...
() managing director & CEO Sean Hall visits Proactive's Sydney studio following participation at the Australian Pharmacy Professional Conference &...
The development and distribution deal is in the form of a heads of agreement. The HoA is with Canada’s fourth largest generic pharmaceutical company (...
New research corroborates the company’s direction of studying the use of NRGBiotic™ to improve gut health. Globally, more than 300 million people suff...
() managing director & CEO Sean Hall catches up with Proactive Investors about the biotech's progress so far in 2019. Hall teases, "We're planning...
Along with Priceline, more than 2100 independent pharmacies will also be able to access Medlab’s nutraceutical range. The cannabis drug developer aims...
() is commercialising a therapeutics pipeline with four strategic pillars as the cannabis drug developer aims to help patients with diagnosed chronic ...
